Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
varicella virus vaccine live new seed process + measles, mumps, and rubella virus vaccine live
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
A **combination vaccine** containing two live attenuated virus vaccine components: - **Varicella virus vaccine live new seed process** (typically derived from the Oka strain via cell culture adaptation and serial passage, with the "new seed process" referring to updated manufacturing or seed-lot methodologies using designated master and working seed stocks[2][4][6]). - **Measles, mumps, and rubella virus vaccine live** (MMR), using attenuated strains from measles (commonly Edmonston strain), mumps (often Jeryl Lynn strain), and rubella (usually RA27/3 strain)[5]. This vaccine induces the host's immune system to generate protective antibodies against all four viruses (measles, mumps, rubella, varicella)[1][3][7]. Its mechanism is the stimulation of active, long-term immunity by presenting antigens derived from weakened viruses, promoting both humoral and cellular immune responses. It is indicated for the prevention of infection by measles, mumps, rubella, and varicella zoster (chickenpox) viruses in children or susceptible adults[1][3][7].
- Brand names
- ProQuadPriorix Tetra
- Other names
- measles, mumps, rubella, and varicella virus vaccine live
Beyond the preview
Go deeper on varicella virus vaccine live new seed process + measles, mumps, and rubella virus vaccine live.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on varicella virus vaccine live new seed process + measles, mumps, and rubella virus vaccine live.